Patents by Inventor Eric Galia
Eric Galia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200101020Abstract: A thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, said dosage form comprising a pharmacologically active ingredient (A), a free physiologically acceptable acid (B) in an amount of from 0.001 wt.-% to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form, and a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol.Type: ApplicationFiled: December 3, 2019Publication date: April 2, 2020Applicant: GRÜNENTHAL GMBHInventors: Lutz BARNSCHEID, Eric GALIA, Sebastian SCHWIER, Ulrike BERTRAM, Anja GEISSLER, Kornelia GRIESSMANN, Johannes BARTHOLOMÄUS
-
Patent number: 10493033Abstract: A thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, said dosage form comprising a pharmacologically active ingredient (A), a free physiologically acceptable acid (B) in an amount of from 0.001 wt.-% to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form, and a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol.Type: GrantFiled: February 21, 2018Date of Patent: December 3, 2019Assignee: GRÜNENTHAL GMBHInventors: Lutz Barnscheid, Eric Galia, Sebastian Schwier, Ulrike Bertram, Anja Geissler, Kornelia Griessmann, Johannes Bartholomäus
-
Publication number: 20190298662Abstract: The invention relates to transdermal therapeutic systems (TTS) which include, as active ingredient, the NMDA receptor antagonist memantine or one of its physiologically compatible salts. The TTSs can be produced and used for treating diseases of the central nervous system.Type: ApplicationFiled: June 17, 2019Publication date: October 3, 2019Inventors: René EIFLER, Michael HORSTMANN, Regine KAUFMANN, Patrick MOHR, Eric GALIA, Wolfgang PRANGE, Stefan BULLER, Klaus PUSECKER, Jan STAMPFUSS, Susanne STOELBEN
-
Patent number: 10363228Abstract: The invention relates to transdermal therapeutic systems (TTS) which include, as active ingredient, the NMDA receptor antagonist memantine or one of its physiologically compatible salts. The TTSs can be produced and used for treating diseases of the central nervous system.Type: GrantFiled: June 17, 2011Date of Patent: July 30, 2019Assignees: LTS Lohmann Therapie-Systeme AG, Gruenenthal GmbHInventors: René Eifler, Michael Horstmann, Regine Kaufmann, Patrick Mohr, Eric Galia, Wolfgang Prange, Stefan Buller, Klaus Pusecker, Jan Stampfuss, Susanne Stoelben
-
Publication number: 20180326067Abstract: A thermoformed, tamper-resistant pharmaceutical dosage form comprises: a) a pharmacologically active ingredient; b) a polyalkylene oxide having a weight average molecular weight of more than 200,000 g/mol; and c) a zinc component, wherein the content of said zinc component is at least 1 ppm, relative to the total weight of the pharmaceutical dosage form. When the pharmacologically active ingredient is effective against pain, the pharmaceutical dosage form may be used in a method of treating pain. When the pharmacologically active ingredient has abuse potential, the pharmaceutical dosage form may be used in a method of reducing the incidence of the abuse of said pharmacologically active ingredient.Type: ApplicationFiled: July 20, 2018Publication date: November 15, 2018Applicant: GRÜNENTHAL GMBHInventors: LUTZ BARNSCHEID, ERIC GALIA, ANJA GEIßLER, JANA PÄTZ, SEBASTIAN SCHWIER, JULIA BARONSKY-PROBST
-
Patent number: 10080721Abstract: The invention relates to a hot-melt extruded pharmaceutical dosage form with controlled release of a pharmacologically active ingredient (A) embedded in a matrix comprising a polymer (C), the dosage form exhibiting a breaking strength of at least 300 N and having an oblong shape comprising a longitudinal direction of extension, a transversal direction of extension orthogonal to the longitudinal direction of extension, a front side, an opposite back side and a circumferential rim between said front and back side; wherein the core of the pharmaceutical dosage form has a morphological orientation caused by hot-melt extrusion that is substantially orthogonal to the longitudinal direction of extension of the dosage form; and/or the release per area of the pharmacologically active ingredient (A) through the front side and the opposite back side is faster than the release through the circumferential rim.Type: GrantFiled: July 21, 2010Date of Patent: September 25, 2018Assignee: GRUENENTHAL GMBHInventors: Lutz Barnscheid, Eric Galia
-
Patent number: 10064945Abstract: A thermoformed, tamper-resistant pharmaceutical dosage form comprises: a) a pharmacologically active ingredient; b) a polyalkylene oxide having a weight average molecular weight of more than 200,000 g/mol; and c) a zinc component, wherein the content of said zinc component is at least 1 ppm, relative to the total weight of the pharmaceutical dosage form. When the pharmacologically active ingredient is effective against pain, the pharmaceutical dosage form may be used in a method of treating pain. When the pharmacologically active ingredient has abuse potential, the pharmaceutical dosage form may be used in a method of reducing the incidence of the abuse of said pharmacologically active ingredient.Type: GrantFiled: May 10, 2013Date of Patent: September 4, 2018Assignee: GRUENENTHAL GMBHInventors: Lutz Barnscheid, Eric Galia, Anja Geißler, Jana Pätz, Sebastian Schwier, Julia Baronsky-Probst
-
Publication number: 20180177732Abstract: A thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, said dosage form comprising a pharmacologically active ingredient (A), a free physiologically acceptable acid (B) in an amount of from 0.001 wt.-% to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form, and a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol.Type: ApplicationFiled: February 21, 2018Publication date: June 28, 2018Applicant: GRÜNENTHAL GMBHInventors: Lutz BARNSCHEID, Eric GALIA, Sebastian SCHWIER, Ulrike BERTRAM, Anja GEISSLER, Kornelia GRIESSMANN, Johannes BARTHOLOMÄUS
-
Patent number: 9925146Abstract: A thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, said dosage form comprising a pharmacologically active ingredient (A), a free physiologically acceptable acid (B) in an amount of from 0.001 wt.-% to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form, and a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol.Type: GrantFiled: September 1, 2015Date of Patent: March 27, 2018Assignee: GRÜNENTHAL GMBHInventors: Lutz Barnscheid, Eric Galia, Sebastian Schwier, Ulrike Bertram, Anja Geissler, Kornelia Griessmann, Johannes Bartholomäus
-
Patent number: 9750701Abstract: The invention relates to a pharmaceutical dosage form, preferably with controlled release of a pharmacologically active compound (A) contained therein, the pharmaceutical dosage form very preferably being tamper-resistant and most preferably having a breaking strength B1 of at least 500 N in direction of extension E1 and having a breaking strength B2 of less than 500 N in direction of extension E2.Type: GrantFiled: December 11, 2015Date of Patent: September 5, 2017Assignee: GRÜNENTHAL GMBHInventors: Eugeen Marie Jozef Jans, Filip René Irena Kiekens, Jody Firmin Marceline Voorspoels, Anne Faure, Iris Ziegler, Elisabeth Arkenau-Maric, Lutz Barnscheid, Johannes Bartholomäus, Marc Frevel, Eric Galia, Andrea Schüessele
-
Publication number: 20160199305Abstract: The invention relates to a pharmaceutical dosage form, preferably with controlled release of a pharmacologically active compound (A) contained therein, the pharmaceutical dosage form very preferably being tamper-resistant and most preferably having a breaking strength B1 of at least 500 N in direction of extension E1 and having a breaking strength B2 of less than 500 N in direction of extension E2.Type: ApplicationFiled: December 11, 2015Publication date: July 14, 2016Applicant: GRÜNENTHAL GMBHInventors: EUGEEN MARIE JOZEF JANS, FILIP RENÉ IRENA KIEKENS, JODY FIRMIN MARCELINE VOORSPOELS, ANNE FAURE, IRIS ZIEGLER, ELISABETH ARKENAU-MARIC, LUTZ BARNSCHEID, JOHANNES BARTHOLOMÄUS, MARC FREVEL, ERIC GALIA, ANDREA SCHÜESSELE
-
Publication number: 20150366809Abstract: A thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, said dosage form comprising a pharmacologically active ingredient (A), a free physiologically acceptable acid (B) in an amount of from 0.001 wt.-% to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form, and a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol.Type: ApplicationFiled: September 1, 2015Publication date: December 24, 2015Applicant: GRÜNENTHAL GMBHInventors: Lutz BARNSCHEID, Eric GALIA, Sebastian SCHWIER, Ulrike BERTRAM, Anja GEISSLER, Kornelia GRIESSMANN, Johannes BARTHOLOMÄUS
-
Publication number: 20140322323Abstract: The invention relates to a pharmaceutical dosage form, preferably with controlled release of a pharmacologically active compound (A) contained therein, the pharmaceutical dosage form very preferably being tamper-resistant and most preferably having a breaking strength B1 of at least 500 N in direction of extension E1 and having a breaking strength B2 of less than 500 N in direction of extension E2.Type: ApplicationFiled: April 25, 2014Publication date: October 30, 2014Applicant: GRÜNENTHAL GMBHInventors: EUGEEN MARIE JOZEF JANS, FILIP RENÉ IRENA KIEKENS, JODY FIRMIN MARCELINE VOORSPOELS, ANNE FAURE, IRIS ZIEGLER, ELISABETH ARKENAU-MARIC, LUTZ BARNSCHEID, JOHANNES BARTHOLOMÄUS, MARC FREVEL, ERIC GALIA, ANDREA SCHÜESSELE
-
Publication number: 20140194455Abstract: A thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, said dosage form comprising a pharmacologically active ingredient (A), a free physiologically acceptable acid (B) in an amount of from 0.001 wt.-% to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form, and a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol.Type: ApplicationFiled: February 28, 2014Publication date: July 10, 2014Applicant: GRUNENTHAL GMBHInventors: Lutz BARNSCHEID, Eric GALIA, Sebastian SCHWIER, Ulrike BERTRAM, Anja GEISSLER, Kornelia GRIESSMANN, Johannes BARTHOLOMÄUS
-
Publication number: 20130303623Abstract: A thermoformed, tamper-resistant pharmaceutical dosage form comprises: a) a pharmacologically active ingredient; b) a polyalkylene oxide having a weight average molecular weight of more than 200,000 g/mol; and c) a zinc component, wherein the content of said zinc component is at least 1 ppm, relative to the total weight of the pharmaceutical dosage form. When the pharmacologically active ingredient is effective against pain, the pharmaceutical dosage form may be used in a method of treating pain. When the pharmacologically active ingredient has abuse potential, the pharmaceutical dosage form may be used in a method of reducing the incidence of the abuse of said pharmacologically active ingredient.Type: ApplicationFiled: May 10, 2013Publication date: November 14, 2013Inventors: LUTZ BARNSCHEID, ERIC GALIA, ANJA GEIßLER, JANA PÄTZ, SEBASTIAN SCHWIER, JULIA BARONSKY-PROBST
-
Publication number: 20130251759Abstract: The invention relates to a pharmaceutical dosage form, preferably with controlled release of a pharmacologically active compound (A) contained therein, the pharmaceutical dosage form very preferably being tamper-resistant and most preferably having a breaking strength B1 of at least 500 N in direction of extension E1 and having a breaking strength B2 of less than 500 N in direction of extension E2.Type: ApplicationFiled: January 16, 2013Publication date: September 26, 2013Applicant: GRUENENTHAL GMBHInventors: EUGEEN MARIE JOZEF JANS, FILIP RENÉ IRENA KIEKENS, JODY FIRMIN MARCELINE VOORSPOELS, ANNE FAURE, IRIS ZIEGLER, ELISABETH ARKENAU-MARIC, LUTZ BARNSCHEID, JOHANNES BARTHOLOMUÄS, MARC FREVEL, ERIC GALIA, ANDREA SCHÜESSELE
-
Patent number: 8383152Abstract: The invention relates to a pharmaceutical dosage form, preferably with controlled release of a pharmacologically active compound (A) contained therein, the pharmaceutical dosage form very preferably being tamper-resistant and most preferably having a breaking strength B1 of at least 500 N in direction of extension E1 and having a breaking strength B2 of less than 500 N in direction of extension E2.Type: GrantFiled: January 23, 2009Date of Patent: February 26, 2013Assignee: Gruenenthal GmbHInventors: Eugeen Marie Jozef Jans, Filip René Irena Kiekens, Jody Firmin Marceline Voorspoels, Anne Faure, Elisabeth Arkenau-Maric, Lutz Barnscheid, Johannes Bartholomäus, Marc Frevel, Eric Galia, Iris Ziegler, Andrea Schüssele
-
Publication number: 20120136021Abstract: A thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, said dosage form comprising a pharmacologically active ingredient (A), a free physiologically acceptable acid (B) in an amount of from 0.001 wt.-% to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form, and a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol.Type: ApplicationFiled: January 5, 2012Publication date: May 31, 2012Applicant: GRUNENTHAL GMBHInventors: Lutz Barnscheid, Eric Galia, Sebastian Schwier, Ulrike Bertram, Anja Geissler, Kornelia Griessmann, Johannes Bartholomäus
-
Publication number: 20110038930Abstract: The invention relates to a hot-melt extruded pharmaceutical dosage form with controlled release of a pharmacologically active ingredient (A) embedded in a matrix comprising a polymer (C), the dosage form exhibiting a breaking strength of at least 300 N and having an oblong shape comprising a longitudinal direction of extension, a transversal direction of extension orthogonal to the longitudinal direction of extension, a front side, an opposite back side and a circumferential rim between said front and back side; wherein the core of the pharmaceutical dosage form has a morphological orientation caused by hot-melt extrusion that is substantially orthogonal to the longitudinal direction of extension of the dosage form; and/or the release per area of the pharmacologically active ingredient (A) through the front side and the opposite back side is faster than the release through the circumferential rim.Type: ApplicationFiled: July 21, 2010Publication date: February 17, 2011Applicant: Grunenthal GmbHInventors: Lutz BARNSCHEID, Eric Galia
-
Patent number: 7772429Abstract: The invention relates to the compound of the formula 1 and to its physiologically acceptable salts. The compound is suitable, for example, as a hypolipidemic.Type: GrantFiled: March 26, 2007Date of Patent: August 10, 2010Assignee: Sanofi-Aventis Deutschland GmbHInventors: Gerhard Jaehne, Wendelin Frick, Andreas Lindenschmidt, Stefanie Flohr, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer, Eric Galia, Heiner Glombik